2. SELECT the status for worldwide and clinical trials Phase III. Use the (S) connector so they are in the same field.

3. SELECT the name of the drug you want information about.

4. Combine sets.

?b 128
File  128:PHARMAPROJECTS 1980-2006/Aug W1
        (c) 2006 Informa UK Ltd
                             
      Set    Items   Description
      ---    -----   -----------
?S  WORLD(S)III
             36033   WORLD 
              3970    III 
      S1       506   WORLD(S)III 
?S  PIOGLITAZONE/NA
      S2         4   PIOGLITAZONE/NA 
?S S1  AND S2
               506   S1 
                 4   S2 
      S3         1   S1 AND S2 

5. TYPE the complete record using Format 9 to see the status of the drug worldwide.

Note that Full format in this database is Format 19 and includes the chemical structure.

?T  S3/9/1

    3/9/1   
DIALOG(R)File  128:PHARMAPROJECTS 
(c)  2006 Informa UK Ltd. All rts. reserv. 
                         
0042371           ** Image available ** 
DRUG  NAME:     pioglitazone HCl + TAK-536 
ORIGINATOR:   Takeda (Japan) [Phase III Clinical Trial] 
SYNONYMS:       TAK-536 + pioglitazone HCl 
CAS  REG NO:   112529-15-4 
               147403-03-0 
ROTATABLE  BONDS: 8 
MOL  FORMULA: C44H41CLN6O8S 
HYDROGEN  BOND ACCEPTORS: 7 
HYDROGEN  BOND DONORS: 2 
ALOGP:  5.32 
MOL  WEIGHT:   456.46 
CHEM  NAME:     2,4-Thiazolidinedione,  5-((4-(2-(5-ethyl-2-
pyridinyl)ethoxy)p henyl)methyl)-, monohydrochloride  (+/-) + 1H- 
Benzimidazole-7-carboxylic acid,  1((2'-(2,5-dihydro-5-oxo-1,2,4-
oxadiazol-3-y          l)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy 
                       
TEXT:               Takeda is developing a fixed-dose combination 
of its antidiabetic  PPAR-gamma agonist pioglitazone and its 
angiotensin II type 1 antagonist  TAK-536 (both qv), for the 
treatment of Type II diabetes associated  with hypertension.

Details of the Phase III clinical trials

Status of the drug in countries around the world

   Phase III 
   
      Phase III trials are underway (JCN  Web Page, 21 Jul 2006). 
Entered  by IL on 21/7/2006. 

STATUS:  (Active) 
         World            Phase III Clinical Trial 
         USA              Phase III Clinical Trial 
   
 THER.  CLASS: F9B   (Formulation, fixed-dose  combinations) 
               A10B       (Antidiabetic) 
               C2B2       (Antihypertensive, renin system) 
 ORIGIN:       CH-SY      (Chemical, synthetic) 
 RTE  OF ADMIN:A-PO       (Alimentary, po) 
 INDICATIONS:  Diabetes, Type II C3 Phase III Clinical Trial 
               Hypertension, general C3 Phase III  Clinical Trial 
 PHARM.  CODE: PPAR-G-AG Peroxisome proliferator-activated receptor 
 gamma agonist   Receptor, Biochemical, Peroxisome 
 proliferatoractivated receptor  gamma agonist PPAR-gamma  agonist 
 R-B-PPAR-G-AG ANG-2-1-AN Angiotensin II 1  antagonist  
 Physiological, Hormonal, Angiotensin II 1  antagonist Angiotonin
 II 1 antagonist Hypertensin II 1  antagonist Angiotensin II AT1
 antagonist Hypertensin II AT1  antagonist P-H-ANG-2-1-AN 
   
 TARGET  DATA CODE: 5468: PPARG; 5468: NR1C3; 5468: PPARG1; 5468:
 PPARG2; 5468:  HUMPPARG; 5468: PPAR-gamma; 185: AGTR1; 185: AT1;
 185: AG2S; 185: AT1B;  185: AT2R1; 185: HAT1R; 185: AGTR1A; 185:
 AGTR1B; 185: AT2R1A; 185: AT2R1B;  185: angiotensin receptor 1;
 185: angiotensin receptor 1B